Neurodegenerative disorders and their treatment

Drug News and Perspectives

Volumn 20, Issue 6, 2007, Pages 407-412

  Karran, Eric ^a,b   Palmer, Alan M ^a,b  

^a Eli Lilly ^*  (United Kingdom)

^b Society for Medicines Research (SMR) Committee   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN ANTIBODY; APTIGANEL; BAPINEUZUMAB; CD 668863; CD 681301; CP 668863; CP 681301; CYCLIN DEPENDENT KINASE INHIBITOR; DISUFENTON SODIUM; DOPAMINE RECEPTOR STIMULATING AGENT; ELIPRODIL; FLECAINIDE; GAMMA SECRETASE INHIBITOR; GAVESTINEL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOTAURINE; LAMOTRIGINE; LEVO FLURBIPROFEN; LEVODOPA; LEVODOPA METHYL ESTER; LIDOCAINE; LY 2062430; LY 450139; RASAGILINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MULTIPLE SCLEROSIS; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; STROKE; SYMPTOMATOLOGY; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANIMALS; BRAIN INJURIES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STROKE;

EID: 36849012519     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Filippini, G., Munari, L., Incorvaia, B. et al. Interferons in relapsing remitting multiple sclerosis: A systematic review. Lancet 2003, 361: 545-52.
2. Hardy, J. and Higgins, G.A. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 286: 184-5.
3. Paisan-Ruiz, C., Jain, S., Evans, E.W. et al. Cloning of the gene containing mutations that cause PARK-8-linked Parkinson's disease. Neuron 2004, 44: 595-600.
4. Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E., Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 1988, 85: 4051-5.
5. Hutton, M., Lendon, C.L., Rizzu, P. et al. Association of missense and 5′ splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393: 702-6.
6. Johnston, T.H. and Brotchie, J.M. Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs 2006, 7: 25-32.
7. Dobrossy, M.D. and Dunnett, S.B. Optimising plasticity: Environmental and training associated factors in transplant-mediated brain repair. Rev Neurosci 2005, 16: 1-21.
8. Palmer A.M. and Carter N. The role of sodium channels in disease. Drugs News Perspect 2001, 14: 568-76.
9. Smith, K.J. Sodium channels and multiple sclerosis: Roles in symptom production, damage and therapy. Brain Pathol 2007, 17: 230-42.
10. Muir, K.W. and Lees, K.R. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003: CD001244.
11. Dawson, D.A., Wadsworth, G. and Palmer, A.M. A comparative assessment of the efficacy and side effect liability of neuroprotective compounds in experimental stroke. Brain Res 2001, 892: 344-50.
12. Savitz, S.I. and Fisher, M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007, 61: 396-402.
13. Marklund, N., Bakshi, A., Castelbuono, D.J., Conte, V. and McIntosh, T.K. Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des 2006, 12: 1645-80.
14. Davies, A.R. Hypothermia improves outcome from traumatic brain injury. Crit Care Resusc 2005, 7: 238-43.
15. Muir, K.W. Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6: 53-60.